Woeful Outlook For Drugmakers But No Eurozone Exit

BMI View: Following an internal workshop on the prospect of a Greek exit from the eurozone, BMI's Country Risk team have decided to continue to stick with our 'muddle through' scenario and we expect Greece to remain in the European Economic and Monetary Union. However, this is a relatively low-conviction call, with huge risks to the downside.[1] As a result, BMI's Pharmaceuticals and Healthcare team have broadly maintained the core forecast scenario for the drug market, with our existing economic assumptions remaining intact.

To read the full article, please choose one of the following options: